177Lu-ACT319 in FAP Expressing Solid Tumors
A Phase 1/2 Study of 177Lu-ACT319 in Patients With Advanced FAP Expressing Solid Tumors
This is a study of 177Lu -ACT319 in participants with the following cancers: pancreatic ductal adenocarcinoma (PDAC), biliary tract carcinoma (BTC), that is advanced, and for which there are no valid treatment options. Participants must have cancer that expresses protein called fibroblast activation protein (FAP). The purpose of this study is to evaluate safety, how the body tolerates, and how well ACT319 works in treating cancer. In addition, this study will evaluate how much 177Lu-ACT319 gets into the bloodstream, how it is broken down, and how long it takes the body to get rid of it. For each participant, the study will last approximately 2 years.
A separate group of patients with other FAP expressing solid tumor types will be evaluated by PET/CT or SPECT/CT imaging for the intensity of target expression.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Part 1A evaluates escalating 177Lu-ACT319 doses in PDAC/BTC to estimate MTD and/or define RDE.
Part 1B is an open-label single-arm exploratory imaging sub-study in other FAP-expressing tumors.
Part 2A randomizes patients with PDAC 1:1 between Recommended Dose for Expansion (RDE and RDE-1 dose levels) to identify an optimized dose regimen/RP2D.
Part 2B may expand at the optimized dose in additional solid tumors selected from emerging data. FAP-positive disease is confirmed by PET/SPECT imaging. Treatment is IV administration every 6 weeks for up to 4 cycles, with up to 2 optional additional cycles based on benefits/safety.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Head of Clinical Operations
- Phone Number: +1-617-780-8045
- Email: info@actithera.com
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and female participants, age ≥ 18 years on the day of signing informed consent.
- Histologically of cytologically confirmed advanced, unresectable and/or metastatic cancer. Participants must be refractory to or not tolerant to existing therapies known to provide clinical benefits for their condition
- At least one measurable lesion per RECIST v1.1 by investigator assessment.
- FAPI PET/SPECT imaging positive.
- Adequate organ and bone marrow function in the 7 days prior to treatment.
- Patient Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
- Anticipated life expectancy of 6 months or higher in the opinion of the investigator.
- Participants with known central nervous system (CNS) metastasis will be eligible if they are clinically stable.
Exclusion Criteria:
- Known hypersensitivity to the active substance, or to any of the excipients of the 177Lu-ACT319.
- Uncontrolled intercurrent illness including, but not limited to, ongoing active infection, uncontrolled diabetes mellitus, symptomatic congestive heart failure, or unstable angina pectoris.
- Participants who have not had resolution of all clinically significant toxic effects of prior systemic cancer therapy, surgery, or radiotherapy to Grade ≤1 - Active clinically significant cardiac disease
- Any major surgery within 4 weeks before enrollment. - Pregnancy or breastfeeding. - Unable or unwilling to comply with all study requirements for clinical visits, examinations, tests, study procedures, and contraception requirements. - Known diagnosis of liver cirrhosis, systemic fibrotic condition such as pulmonary fibrosis, retroperitoneal fibrosis, etc.
- Any concurrent systemic antineoplastic therapy for the underlying disease and/or other investigational agents within a period which is ≤ 5 t1/2 or ≤ 2 weeks (whichever is longer) prior to the first injection of 177Lu-ACT319 (C1D1).
- Treatment with any radiopharmaceutical within 6 weeks of Investigational medicinal product (IMP) or 10 half-lives, whatever is longer.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: 177Lu-ACT319 dose escalation (Part 1A)
In part 1A (dose escalation) - PDAC and BTC will be enrolled |
At Dose level 1 At Dose Level 2 At Dose Level 3 At Dose Level 4 |
|
Experimental: FAP-targeted PET/CT or SPECT/CT imaging (Part 1B)
In part 1B Exploratory imaging cohort to characterize FAP expression across multiple tumor types (different from PDAC/BTC) expressing FAP. |
Low Dose [18F]-FAPI-74 for PET/CT imaging in Part 1B Low Dose 177Lu-ACT319 for imaging in Part 1B |
|
Experimental: 177Lu-ACT319 dose optimization and expansion (Part 2A)
In part 2A; Patients with pancreatic ductal carcinoma will be enrolled for dose optimization and expansion. |
177Lu-ACT319 at Recommended Dose for Expansion 177Lu-ACT319 at one level lower than at Recommended Dose for Expansion |
|
Experimental: 177Lu-ACT319 dose expansion (Part 2B)
In 2B: patients with other solid tumors expressing FAP will be enrolled for dose expansion. |
177Lu-ACT319 at Recommended Dose for Expansion 177Lu-ACT319 at one level lower than at Recommended Dose for Expansion |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Dose escalation (Part 1A)
Time Frame: First 42 days of Cycle 1
|
Incidence of Dose limiting Toxicities (DLTs.) |
First 42 days of Cycle 1
|
|
Imaging/Dosimetry Sub-study (Part 1B)
Time Frame: 2 days post drug administration
|
Ratio of Standardized Uptake Value (SUV) to reference region SUV measured using PET/SPECT imaging. |
2 days post drug administration
|
|
Dose optimization and expansion (Part 2A/2B)
Time Frame: Up to 12 months after the last treatment.
|
Objective Response Rate (ORR) defined as the percentage of participants who achieve a PR or CR to therapy locally assessed by the investigator as measured by RECIST v1.1. |
Up to 12 months after the last treatment.
|
|
Dose escalation (Part 1A)
Time Frame: Up to 24 months from the first treatment cycle administration.
|
Type, Frequency and severity of Adverse events and SAEs in all patients who received at least one dose of the study drug. |
Up to 24 months from the first treatment cycle administration.
|
|
Imaging/Dosimetry Sub-study (Part 1B)
Time Frame: Up to 8 days.
|
Type, frequency and severity of AEs and SAEs. |
Up to 8 days.
|
|
Dose escalation (Part 1A)
Time Frame: Up to 24 months from the first treatment cycle administration.
|
Frequency and duration of dose delays, dose interruptions, and dose reductions. |
Up to 24 months from the first treatment cycle administration.
|
|
Vital Signs: Change from baseline in systolic blood pressure (Part 1B)
Time Frame: Up to 8 days.
|
Change from baseline in systolic blood pressure, measured in millimeters of mercury (mmHg). |
Up to 8 days.
|
|
Vital Signs: Change from baseline in diastolic blood pressure (Part 1B)
Time Frame: Up to 8 days.
|
Change from baseline in diastolic blood pressure, measured in millimeters of mercury (mmHg). |
Up to 8 days.
|
|
Vital Signs: Change from baseline in pulse rate (Part 1B)
Time Frame: Up to 8 days.
|
Change from baseline in pulse rate, measured in beats per minute. |
Up to 8 days.
|
|
Vital Signs: Change from baseline in respiratory rate (Part 1B)
Time Frame: Up to 8 days.
|
Change from baseline in respiratory rate, measured in breaths per minute. |
Up to 8 days.
|
|
Vital Signs: Change from baseline in body temperature (Part 1B)
Time Frame: Up to 8 days.
|
Change from baseline in body temperature, measured in degrees Celsius. |
Up to 8 days.
|
|
ECGs: Change from baseline in ECG heart rate (Part 1B)
Time Frame: Up to 8 days.
|
Change from baseline in heart rate, recorded using a 12-lead electrocardiogram (ECG) and measured in beats per minute. |
Up to 8 days.
|
|
ECGs: Change from baseline in ECG PR interval (Part 1B)
Time Frame: Up to 8 days.
|
Change from baseline in PR interval, recorded using a 12-lead electrocardiogram (ECG) and measured in milliseconds. |
Up to 8 days.
|
|
ECGs: Change from baseline in ECG QRS duration (Part 1B)
Time Frame: Up to 8 days.
|
Change from baseline in QRS duration, recorded using a 12-lead electrocardiogram (ECG) and measured in milliseconds. |
Up to 8 days.
|
|
ECGs: Change from baseline in ECG QT interval (Part 1B)
Time Frame: Up to 8 days.
|
Change from baseline in QT interval, recorded using a 12-lead electrocardiogram (ECG) and measured in milliseconds. |
Up to 8 days.
|
|
Imaging sub-study (Part 1B): Number of participants with clinically significant laboratory abnormalities
Time Frame: Up to 8 days.
|
Number of participants with at least one new or worsened clinically significant abnormality from baseline in hematology, biochemistry, coagulation or other applicable safety laboratory test as assessed by the investigator. Each participant is counted once, regardless of the number of qualifying abnormalities or assessment visits. |
Up to 8 days.
|
|
ECGs: Change from baseline in Fridericia-corrected QT interval (QTcF) (Part 1B)
Time Frame: Up to 8 days.
|
Change from baseline in QT interval corrected for heart rate using Fridericia's formula, recorded using a 12-lead electrocardiogram (ECG) and measured in milliseconds |
Up to 8 days.
|
|
Dose escalation (Part 1A)
Time Frame: First 42 days of Cycle 1
|
MTD and/or RDE as determined by the BOIN dose-escalation algorithm based on observed DLT rates. |
First 42 days of Cycle 1
|
|
Vital Signs: Change from baseline in systolic blood pressure (Part 1A, 2A, 2B)
Time Frame: Up to 24 months from the first treatment cycle administration.
|
Change from baseline in systolic blood pressure, measured in millimeters of mercury (mmHg). |
Up to 24 months from the first treatment cycle administration.
|
|
Vital Signs: Change from baseline in diastolic blood pressure (Part 1A, 2A, 2B)
Time Frame: Up to 24 months from the first treatment cycle administration.
|
Change from baseline in diastolic blood pressure, measured in millimeters of mercury (mmHg). |
Up to 24 months from the first treatment cycle administration.
|
|
Vital Signs: Change from baseline in pulse rate (Part 1A, 2A, 2B)
Time Frame: Up to 24 months from the first treatment cycle administration.
|
Change from baseline in pulse rate, measured in beats per minute. |
Up to 24 months from the first treatment cycle administration.
|
|
Vital Signs: Change from baseline in respiratory rate (Part 1A, 2A, 2B)
Time Frame: Up to 24 months from the first treatment cycle administration.
|
Change from baseline in respiratory rate, measured in breaths per minute. |
Up to 24 months from the first treatment cycle administration.
|
|
Vital Signs: Change from baseline in body temperature (Part 1A, 2A, 2B)
Time Frame: Up to 24 months from the first treatment cycle administration.
|
Change from baseline in body temperature, measured in degrees Celsius. |
Up to 24 months from the first treatment cycle administration.
|
|
ECGs: Change from baseline in ECG heart rate (Part 1A, 2A, 2B)
Time Frame: Up to 24 months from the first treatment cycle administration.
|
Change from baseline in heart rate, recorded using a 12-lead electrocardiogram (ECG) and measured in beats per minute. |
Up to 24 months from the first treatment cycle administration.
|
|
ECGs: Change from baseline in ECG PR interval (Part 1A, 2A, 2B)
Time Frame: Up to 24 months from the first treatment cycle administration.
|
Change from baseline in PR interval, recorded using a 12-lead electrocardiogram (ECG) and measured in milliseconds. |
Up to 24 months from the first treatment cycle administration.
|
|
ECGs: Change from baseline in ECG QRS duration (Part 1A, 2A, 2B)
Time Frame: Up to 24 months from the first treatment cycle administration.
|
Change from baseline in QRS duration, recorded using a 12-lead electrocardiogram (ECG) and measured in milliseconds. |
Up to 24 months from the first treatment cycle administration.
|
|
ECGs: Change from baseline in ECG QT interval (Part 1A, 2A, 2B)
Time Frame: Up to 24 months from the first treatment cycle administration.
|
Change from baseline in QT interval, recorded using a 12-lead electrocardiogram (ECG) and measured in milliseconds. |
Up to 24 months from the first treatment cycle administration.
|
|
ECGs: Change from baseline in Fridericia-corrected QT interval (QTcF) (Part 1A, 2A, 2B)
Time Frame: Up to 24 months from the first treatment cycle administration.
|
Change from baseline in QT interval corrected for heart rate using Fridericia's formula, recorded using a 12-lead electrocardiogram (ECG) and measured in milliseconds. |
Up to 24 months from the first treatment cycle administration.
|
|
ECOG: Change from baseline in ECOG performance status (Part 1A, 2A, 2B)
Time Frame: Up to 24 months from the first treatment cycle administration.
|
Change from baseline in Eastern Cooperative Oncology Group (ECOG) performance-status score. Scores range from 0 to 5, with higher scores indicating worse performance status. |
Up to 24 months from the first treatment cycle administration.
|
|
Dose Escalation (Part 1A): Number of participants with clinically significant laboratory abnormalities
Time Frame: Up to 24 months from the first treatment cycle administration
|
Number of participants with at least one new or worsened clinically significant abnormality from baseline in hematology, biochemistry, coagulation or urinalysis tests, as assessed by the investigator. Each participant is counted once regardless of the number of qualifying abnormalities or assessment visits. |
Up to 24 months from the first treatment cycle administration
|
|
Dose optimization and expansion (Part 2A)
Time Frame: Up to 24 months.
|
Selection of the dose regimen with the most favorable overall benefit-risk profile among the dose levels evaluated in Part 2A (RP2D). |
Up to 24 months.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Dose escalation (Part 1A): Maximum observed blood concentration (Cmax) of total ACT319.
Time Frame: Cycle 1: up to Day 8 post-dose.
|
Maximum observed blood concentration (Cmax) of total ACT319 in blood derived from the blood concentration time data |
Cycle 1: up to Day 8 post-dose.
|
|
Dose escalation (Part 1A): Time of the peak of blood concentration (Tmax) of total ACT319.
Time Frame: Cycle 1: up to Day 8 post-dose.
|
Time after administration to the maximum observed concentration of total ACT319 in blood. |
Cycle 1: up to Day 8 post-dose.
|
|
Dose escalation (Part 1A): Blood concentration plotted against time (AUC) of total ACT319.
Time Frame: Cycle 1: up to Day 8 post-dose.
|
Area under the total ACT319 blood concentration time curve |
Cycle 1: up to Day 8 post-dose.
|
|
Dose escalation (Part 1A): Blood Elimination time for ACT319 (t1/2).
Time Frame: Cycle 1: up to Day 8 post-dose.
|
Terminal elimination half-life of total ACT319 derived from the blood concentration time data. |
Cycle 1: up to Day 8 post-dose.
|
|
Dose escalation (Part 1A): Maximum observed blood radioactivity concentration (Cmax) of 177Lu-ACT319.
Time Frame: Cycle 1: Up to Day 8 post-dose.
|
Maximum observed radioactivity concentration in blood following administration of 177Lu-ACT319 |
Cycle 1: Up to Day 8 post-dose.
|
|
Dose escalation (Part 1A): Time to maximum observed blood radioactivity concentration (Tmax) of 177Lu-ACT319.
Time Frame: Cycle 1: up to Day 8 post-dose.
|
Time after administration of 177Lu-ACT319 to the maximum observed radioactivity concentration in blood |
Cycle 1: up to Day 8 post-dose.
|
|
Dose escalation (Part 1A): Area under the blood radioactivity concentration curve (AUC) of total 177Lu-ACT319.
Time Frame: Cycle 1: up to Day 8 post-dose.
|
Area under the blood radioactivity concentration time curve following administration of 177Lu-ACT319. |
Cycle 1: up to Day 8 post-dose.
|
|
Dose escalation (Part 1A): Elimination half-life (t1/2) of 177Lu-ACT319 in blood
Time Frame: Cycle 1: up to Day 8 post-dose.
|
Elimination half-life derived from blood radioactivity measurements following administration of 177Lu-ACT319. |
Cycle 1: up to Day 8 post-dose.
|
|
Dose escalation (Part 1A): Cumulative amount of 177Lu-ACT319 excreted in urine (Ae).
Time Frame: Cycle 1: up to Day 8 post-dose.
|
Culminative radioactivity excreted in urine following administration of 177Lu-ACT319 over the planned urine collection interval. |
Cycle 1: up to Day 8 post-dose.
|
|
Dose escalation (Part 1A): Cumulative percentage of 177Lu-ACT319 excreted in urine (Ae%).
Time Frame: Cycle 1: up to Day 8 post-dose.
|
Culminative radioactivity excreted in urine expressed as a percentage of administered radioactivity over the planned urine collection interval. |
Cycle 1: up to Day 8 post-dose.
|
|
Dose escalation (Part 1A): Renal clearance (CLR) of 177Lu-ACT319.
Time Frame: Cycle 1: up to Day 8 post-dose.
|
Renal Clearance derived from urinary radioactivity excretion and corresponding blood radioactivity exposure following administration of 177Lu-ACT319 |
Cycle 1: up to Day 8 post-dose.
|
|
Dose escalation (Part 1A)
Time Frame: Cycle 1: up to Day 8 post-dose.
|
Radioactivity uptake in normal organs and tumor lesions. |
Cycle 1: up to Day 8 post-dose.
|
|
Dose escalation (Part 1A)
Time Frame: Cycle 1: Up to Day 8
|
Tumor-to-background ratio defined as the ratio of the lesion SUV over the reference region SUV. |
Cycle 1: Up to Day 8
|
|
Dose optimization and expansion (Part 2A and 2B)
Time Frame: Up to 24 months from the first treatment cycle administration.
|
Type, frequency and severity of AEs and SAEs using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v6.0. |
Up to 24 months from the first treatment cycle administration.
|
|
Vital Signs: Dose optimization and expansion (Parts 2A and 2B): Change from baseline in systolic blood pressure
Time Frame: Up to 24 months from the first treatment cycle administration
|
Change from baseline in systolic blood pressure, measured in millimeters of mercury (mmHg). |
Up to 24 months from the first treatment cycle administration
|
|
Vital Signs: Dose optimization and expansion (Parts 2A and 2B): Change from baseline in diastolic blood pressure
Time Frame: Up to 24 months the first treatment cycle administration.
|
Change from baseline in diastolic blood pressure, measured in millimeters of mercury (mmHg). |
Up to 24 months the first treatment cycle administration.
|
|
Vital Signs: Dose optimization and expansion (Parts 2A and 2B): Change from baseline in pulse rate.
Time Frame: Up to 24 months the first treatment cycle administration.
|
Change from baseline in pulse rate, measured in beats per minute. |
Up to 24 months the first treatment cycle administration.
|
|
Vital Signs: Dose optimization and expansion (Parts 2A and 2B): Change from baseline in respiratory rate
Time Frame: Up to 24 months the first treatment cycle administration.
|
Change from baseline in respiratory rate, measured in breaths per minute. |
Up to 24 months the first treatment cycle administration.
|
|
Vital Signs: Dose optimization and expansion (Parts 2A and 2B): Change from baseline in body temperature
Time Frame: Up to 24 months the first treatment cycle administration.
|
Change from baseline in body temperature, measured in degrees Celsius. |
Up to 24 months the first treatment cycle administration.
|
|
ECGs: Dose optimization and expansion (Parts 2A and 2B): Change from baseline in ECG heart rate
Time Frame: Up to 24 months the first treatment cycle administration.
|
Change from baseline in heart rate, recorded using a 12-lead electrocardiogram (ECG) and measured in beats per minute. |
Up to 24 months the first treatment cycle administration.
|
|
ECGs: Dose optimization and expansion (Parts 2A and 2B): Change from baseline in ECG PR interval,
Time Frame: Up to 24 months the first treatment cycle administration.
|
Change from baseline in PR interval, recorded using a 12-lead electrocardiogram (ECG) and measured in milliseconds. |
Up to 24 months the first treatment cycle administration.
|
|
ECGs: Dose optimization and expansion (Parts 2A and 2B): Change from baseline in ECG QRS duration.
Time Frame: Up to 24 months the first treatment cycle administration.
|
Change from baseline in QRS duration, recorded using a 12-lead electrocardiogram (ECG) and measured in milliseconds. |
Up to 24 months the first treatment cycle administration.
|
|
ECGs: Dose optimization and expansion (Parts 2A and 2B): Change from baseline in ECG QT interval.
Time Frame: Up to 24 months the first treatment cycle administration.
|
Change from baseline in QT interval, recorded using a 12-lead electrocardiogram (ECG) and measured in milliseconds. |
Up to 24 months the first treatment cycle administration.
|
|
ECGs: Dose optimization and expansion (Parts 2A and 2B): Change from baseline in Fridericia-corrected QT interval (QTcF).
Time Frame: Up to 24 months the first treatment cycle administration.
|
Change from baseline in QT interval corrected for heart rate using Fridericia's formula, recorded using a 12-lead electrocardiogram (ECG) and measured in milliseconds. |
Up to 24 months the first treatment cycle administration.
|
|
ECOGs: Dose optimization and expansion (Parts 2A and 2B): Change from baseline in ECOG performance status
Time Frame: Up to 24 months the first treatment cycle administration.
|
Change from baseline in Eastern Cooperative Oncology Group (ECOG) performance-status score. |
Up to 24 months the first treatment cycle administration.
|
|
Dose optimization and expansion (Parts 2A and 2B): Number of participants with clinically significant laboratory abnormalities.
Time Frame: Up to 24 months the first treatment cycle administration.
|
Number of participants with at least one new or worsened clinically significant abnormality from baseline in hematology, biochemistry, coagulation or urinalysis. Each participant is counted once regardless of the number of qualifying abnormalities or assessment visits. |
Up to 24 months the first treatment cycle administration.
|
|
Dose optimization and expansion (Part 2A and 2B)
Time Frame: Up to 24 months from the first treatment cycle administration.
|
Frequency and duration of dose delays, dose interruptions, and dose reductions. |
Up to 24 months from the first treatment cycle administration.
|
|
Dose optimization and expansion (Part 2A and 2B)
Time Frame: up to 12 months after last cycle.
|
Progression Free Survival (PFS) determined as the time from C1D1 to the date of progression, defined as the first documented progression as per RECIST v1.1 or death for any cause. |
up to 12 months after last cycle.
|
|
Dose optimization and expansion (Part 2A and 2B)
Time Frame: Up to 24 months from the first treatment cycle administration.
|
Overall Survivor (OS) defined as the time from C1D1 to death from any cause |
Up to 24 months from the first treatment cycle administration.
|
|
Dose optimization and expansion (Part 2A and 2B)
Time Frame: Up to 12 months.
|
Disease control Rate (DCR) defined as the percentage of participants who have achieved CR, PR, or SD. |
Up to 12 months.
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Site
- Neoplasms
- Intestinal Diseases
- Neoplasms by Histologic Type
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Digestive System Diseases
- Gastrointestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Head and Neck Neoplasms
- Neoplasms, Glandular and Epithelial
- Colonic Diseases
- Carcinoma
- Neoplasms, Connective and Soft Tissue
- Carcinoma, Squamous Cell
- Squamous Cell Carcinoma of Head and Neck
- Colorectal Neoplasms
- Sarcoma
- Physical Phenomena
- Electromagnetic Phenomena
- Magnetic Phenomena
- Electromagnetic Radiation
- Radiation
- Radiation, Ionizing
- X-Rays
Other Study ID Numbers
Other Study ID Numbers
- ACT319-101
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.